Stopping GLP-1 Drugs Increases Heart Attack, Stroke Risk

Discontinuing GLP-1 receptor agonist medications, commonly prescribed for type 2 diabetes and weight management, may significantly increase the risk of cardiovascular events such as heart attack, stroke, and death. A large-scale study, the findings of which were presented at the American Heart Association's Scientific Sessions 2024, suggests that the cardiovascular benefits associated with these drugs can diminish rapidly after treatment cessation. Specifically, patients who stopped taking GLP-1 medications experienced a 22% higher risk of experiencing a heart attack, stroke, or death within two years compared to individuals who continued their treatment regimen. This elevated risk underscores the long-term cardiovascular protective effects of these drugs, which extend beyond their primary indications for glycemic control and weight loss.

The study analyzed data from a substantial cohort of patients, though the exact number was not specified in the initial report. The research focused on individuals who had been prescribed GLP-1 receptor agonists, including widely recognized medications such as Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide). These drugs mimic the action of the incretin hormone GLP-1, which plays a crucial role in regulating blood sugar levels and promoting satiety. Beyond their metabolic effects, clinical trials have previously demonstrated that semaglutide and tirzepatide can reduce the risk of major adverse cardiovascular events by up to 20% in individuals with established cardiovascular disease or multiple risk factors. The current study extends these findings by investigating the consequences of treatment withdrawal.

Researchers observed that the protective effects of GLP-1 medications on the cardiovascular system began to wane relatively quickly after patients ceased taking them. The 22% increased risk of heart attack, stroke, and death was identified after a follow-up period of two years off the medication. This finding is particularly significant given the growing popularity of these drugs for both therapeutic and off-label weight loss purposes. The implications of this study suggest that patients considering stopping these medications, whether due to side effects, cost, or achieving treatment goals, should engage in a thorough discussion with their healthcare providers about the potential cardiovascular risks and explore strategies for mitigating them. The study did not detail specific management strategies for patients discontinuing treatment but highlighted the importance of ongoing medical supervision.

The study's presentation at the American Heart Association's Scientific Sessions 2024 places these findings within the context of leading cardiovascular research and clinical practice updates. The American Heart Association is a non-profit organization in the United States that funds cardiovascular medical research and spreads the word about cardiovascular disease. The findings are expected to inform clinical guidelines and patient counseling regarding the long-term use and discontinuation of GLP-1 receptor agonists. Further research may be warranted to explore the precise mechanisms by which cardiovascular protection is lost upon cessation and to identify patient subgroups who may be at particularly high risk.